02:27 PM EST, 03/03/2025 (MT Newswires) -- Voyager Therapeutics ( VYGR ) reported positive results Monday from the single ascending dose trial of its investigational antibody VY7523, developed to selectively inhibit the spread of pathological tau in Alzheimer's disease.

Data from the trial demonstrated the safety, tolerability, and dose-proportional pharmacokinetics of single intravenous doses in 48 healthy volunteers, the company said.

The drug was well tolerated across all six ascending dose cohorts, meeting the primary objective of the trial, with no serious adverse events, severe adverse events, or infusion reactions reported.

Voyager said it has initiated a multiple ascending dose trial of the drug in patients with early Alzheimer's disease, which is expected to generate initial tau positron emission tomography (PET) imaging data in H2 2026.

Voyager shares were down nearly 3% in recent trading.

Price: 3.97, Change: -0.11, Percent Change: -2.70